NASDAQ:URGN

Urogen Pharma Stock News

Healthcare > Biotechnology

Buy URGN

*Your capital is at risk

$26.60

+0.0600 (+0.226%)

At Close: Jun 03, 2026

UroGen Pharma to Present at Upcoming Investor Conferences

08:00am, Thursday, 29'th Aug 2024

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod

UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript

03:05pm, Tuesday, 13'th Aug 2024

UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2024 Earnings Call August 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head, Investor Relations Liz Barrett - President and Chief Executive Officer

Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates

10:16am, Tuesday, 13'th Aug 2024

Urogen Pharma (URGN) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.03 per share a year ago.

Does Urogen Pharma (URGN) Have the Potential to Rally 171.05% as Wall Street Analysts Expect?

10:56am, Friday, 02'nd Aug 2024

The average of price targets set by Wall Street analysts indicates a potential upside of 171.1% in Urogen Pharma (URGN). While the effectiveness of this highly sought-after metric is questionable, the

Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?

11:05am, Thursday, 01'st Aug 2024

Urogen Pharma (URGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High?

10:56am, Wednesday, 17'th Jul 2024

The average of price targets set by Wall Street analysts indicates a potential upside of 149% in Urogen Pharma (URGN). While the effectiveness of this highly sought-after metric is questionable, the p

UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

10:51pm, Monday, 17'th Jun 2024

UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

04:46pm, Monday, 17'th Jun 2024

PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci

Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?

06:01am, Monday, 17'th Jun 2024

Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ter

Uber Advertising Announces Exclusive Partnership with T-Mobile Advertising Solutions

10:54am, Thursday, 13'th Jun 2024

SAN FRANCISCO & BELLEVUE, Wash.--(BUSINESS WIRE)--Today, Uber's advertising division announced an exclusive partnership with T-Mobile Advertising Solutions and its rideshare media network – Octopus

AscellaHealth Chairman and President Bill Oldham Named 2024 Philadelphia Titan 100

10:49am, Thursday, 13'th Jun 2024

BERWYN, Pa.--(BUSINESS WIRE)--Bill Oldham, chairman and president, AscellaHealth, honored as a 2024 Philadelphia Titan 100.

UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

10:45am, Thursday, 13'th Jun 2024

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today an

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by